Role of Protein Targeting to Glycogen (PTG) in the Regulation of Protein Phosphatase-1 Activity*

(Received for publication, April 24, 1997, and in revised form, June 2, 1997)

Matthew J. Brady Dagger , John A. Printen Dagger §, Cynthia Corley Mastick Dagger and Alan R. Saltiel Dagger §

From the Dagger  Department of Cell Biology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105 and the § Department of Physiology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

We have recently cloned from 3T3-L1 adipocytes a novel glycogen-targeting subunit of protein phosphatase-1, termed PTG (Printen, J. A., Brady, M. J., and Saltiel, A. R. (1997) Science 275, 1475-1478). Differentiation of 3T3-L1 fibroblasts into highly insulin-responsive adipocytes resulted in a marked increase in PTG expression. Immobilized glutathione S-transferase (GST)-PTG fusion protein specifically bound either PP1 or phosphorylase a. Addition of soluble GST-PTG to 3T3-L1 lysates increased PP1 activity against 32P-labeled phosphorylase a by decreasing the Km of PP1 for phosphorylase 5-fold, while having no effect on the Vmax of the dephosphorylation reaction. Alternatively, PTG did not affect PP1 activity against hormone-sensitive lipase. PTG was not a direct target of intracellular signaling, as insulin or forskolin treatment of cells did not activate a kinase capable of phosphorylating PTG in vivo or in vitro. Finally, PTG decreased the ability of DARPP-32 to inhibit PP1 activity from 3T3-L1 adipocyte lysates. These data cumulatively suggest that PTG increases PP1 activity against specific proteins by several distinct mechanisms.


INTRODUCTION

While much attention has been focused on the activation of protein kinase signaling cascades, many enzymes involved in glucose and lipid metabolism are regulated by dephosphorylation (2). As the main physiological hormone controlling glucose utilization, insulin exerts many of its effects through the activation of type 1 protein phosphatase (PP1).1 However, insulin treatment of cells results in the dephosphorylation of only a limited number of proteins, while simultaneously other proteins are phosphorylated (3). This paradox suggests that mechanisms must exist whereby insulin activates discrete pools of PP1, leading to the dephosphorylation of specific target proteins.

PP1 is found in many cellular compartments, including the nucleus, plasma membrane, and glycogen particle. It is thought that the cellular localization of this enzyme is mediated by its association with targeting proteins (4, 5). We have recently identified a novel PP1 glycogen-targeting subunit from 3T3-L1 adipocytes, termed PTG for protein targeting to glycogen (1). PTG is the third member of a family of PP1 glycogen-targeting subunits, which also includes RGL, isolated from muscle (6, 7), and the hepatic GL protein (8, 9). In contrast to the restricted localization of RGL and GL, PTG is highly expressed in all insulin-sensitive tissues.2 In addition to targeting PP1 to the glycogen particle, PTG can also form complexes with PP1 substrate enzymes that regulate glycogen metabolism, namely glycogen synthase, glycogen phosphorylase, and phosphorylase kinase. Overexpression of PTG in the metabolically inactive CHO-IR cell line dramatically increased the levels of basal and insulin-stimulated glycogen synthesis (1). PTG may therefore serve as a scaffolding protein, assembling the proteins involved in glycogen metabolism and priming them for the reception of intracellular signals.

The mechanism by which insulin specifically activates glycogen-targeted PP1 activity remains poorly understood. The proposed phosphorylation and activation of the PP1-RGL complex by pp90RSK (10) has subsequently been challenged (11-15). Further, the two putative PP1 regulatory phosphorylation sites of RGL are not conserved in PTG (1). Therefore, other mechanisms must exist for the regulation and activation of PP1 activity targeted to glycogen by PTG. The results presented here demonstrate that PTG is not a direct target for insulin-activated protein kinases. However, PTG does increase PP1-specific activity against phosphorylase a by three separate mechanisms: by targeting the phosphatase to glycogen, by directly binding and co-localizing PP1 substrates, and by reducing the affinity of PP1 for inhibitor peptides such as DARPP-32.


EXPERIMENTAL PROCEDURES

Materials

Cell culture reagents, IPTG, glycogen phosphorylase b, and phosphorylase kinase were from Life Technologies, Inc. Okadaic acid was purchased from Calbiochem. [32P]Orthophosphate was obtained from ICN, whereas [gamma -32P]ATP (3000 Ci/mmol) and [gamma -35S]ATP (1250 Ci/mmol) were from NEN Life Science Products. [alpha -32P]dCTP (3000 Ci/mmol) and ECL reagent were obtained from Amersham. Glutathione-Sepharose 4B beads and Ni-NTA agarose beads were purchased from Pharmacia Biotech Inc. and Qiagen, respectively. Polyhistidine-tagged DARPP-32 construct was the kind gift of Drs. J. Bibb and A. Nairn (Rockefeller University), while chicken affinity-purified anti-PP1alpha antibody was generously provided by Dr. J. Lawrence (University of Virginia). GluT-4 antibody was from Dr. G. Lienhard (Dartmouth). Horseradish peroxidase-conjugated rabbit anti-chicken IgG was obtained from Accurate Chemical Corp. (Westbury, NY).

Cell Culture

3T3-L1 fibroblasts and CHO-IR cells were maintained as described previously (14, 16). 3T3-L1 fibroblasts were differentiated into adipocytes by a standard protocol (14); adipocytes were routinely used 6-10 days after completion of differentiation. Primary rat adipocytes were isolated from epididymal fat pads and fractionated as described previously (17).

Northern Blot Analysis

Total RNA was isolated from 3T3-L1 fibroblasts and fully differentiated adipocytes by acid guanidinium thiocyanate-phenol-chloroform extraction (Rnasol; Biotex Laboratories). RNA samples (15 µg) were electrophoresed in 1.2% agarose, 2.2 M formaldehyde, 1 × MOPS, and transferred by capillary diffusion to nylon membranes (Hybond, Amersham). Membranes were pre-hybridized for 1 h in FBY hybridization buffer (10% polyethylene glycol, 1.5 × SSPE, 7% SDS) and then hybridized overnight at 65 °C with the 1.0-kilobase EcoRI fragment of PTG, which had been gel-purified and labeled with [alpha -32P]dCTP by random priming (>1 × 109 cpm/µg). The blot was washed for 15 min at 65 °C in 2 × SSC, 0.1% SDS, then washed twice at 65 °C in 0.1 × SSC, 0.1% SDS for 15 min each time. Blots were analyzed by autoradiography. RNA loading was determined by ethidium bromide staining and by probing for beta -actin.

Fusion Protein Expression and Purification

PTG was subcloned into the pGEX-5X-3 expression vector (Pharmacia), and fusion protein was expressed in Escherichia coli DH5alpha . One liter of 2X-YT media plus 100 µg/ml ampicillin was seeded with 10 ml of a saturated overnight culture and allowed to grow at 37 °C for 3.5 h (A600 = 0.5-0.7). Protein expression was induced with 1 mM IPTG for 3 h at 37 °C. Bacteria pellets were resuspended in 20 ml of PBS containing 1 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml aprotinin added just before use and were lysed by two passes through a French press (1,000 p.s.i.). 2 ml of PBS plus 10% Triton X-100 were added to the lysate which was then gently mixed at 4 °C for 15 min. The supernatant from a 27,000 × g, 15-min centrifugation spin was applied to 1 ml of glutathione-Sepharose beads equilibrated in PBS. After 30 min of mixing at 4 °C, the beads were washed five times with PBS and analyzed by SDS-PAGE. This protocol was designed to maximize GST-PTG yield and solubility. Typically, 0.5-1 mg of GST-PTG was isolated per liter of culture. GST-PTG was batch-eluted three times with 5 ml of PBS plus 20 mM glutathione (pH 7.8), followed by concentration with a Centriprep-30 (Amicon). A GST fusion protein comprising the 40-kDa N terminus of RGL (GST-G40) was expressed, purified, and eluted in an identical fashion. E. coli DH5alpha containing a full-length hormone-sensitive lipase GST fusion protein construct (GST-HSL; provided by Dr. C. Baumann, Parke-Davis) were grown to an A600 of 1, and then protein expression was induced with 0.5 mM IPTG for 3 h at 30 °C. GST-HSL was purified as above, and immobilized GST-HSL was labeled using purified protein kinase A catalytic subunit and 50 µM [gamma -32P]ATP (2500 cpm/pmol) at room temperature for 45 min. The beads were washed extensively with PP1 homogenization buffer, and 10 µl of a 50% slurry were used as substrate in the PP1 assay.

A saturated culture of bacteria containing a polyhistidine-tagged DARPP-32 construct was diluted and grown in LB media at 37 °C for 3-4 h until the A600 = 0.4. Protein expression was induced by an overnight incubation with 1 mM IPTG at 30 °C. Bacterial pellets were lysed as above, and the clarified lysate was applied to Ni-NTA agarose affinity resin. After batch elution in 50 mM Tris (pH 6.8), 150 mM NaCl, and 0.5 M imidazole, DARPP-32 was concentrated using a Centriprep-10.

In Vivo and in Vitro Phosphorylation Assays

CHO-IR cells were transiently transfected with a FLAG epitope-tagged PTG construct as described previously (1). 48 h post-transfection, cells were serum-deprived for 3 h in phosphate-free Dulbecco's modified Eagle's medium plus 0.5% calf serum. Cells were then incubated for 1 h in the same media containing 1 mCi/1.5 ml of [32P]orthophosphate. After stimulation, cells were washed three times with ice-cold PBS and lysed in HNTG buffer (14, 18) plus protease inhibitors, and anti-FLAG immunoprecipitations were performed as described (1). Replicate culture plates were treated in parallel without [32P]orthophosphate, and in vitro kinase assays were performed on the cell extracts as below.

3T3-L1 adipocytes were serum-starved for 3 h in Krebs-Ringer buffer with 30 mM Hepes (pH 7.4) plus 0.5% BSA and 2.5 mM glucose. After treatment, cells were washed three times with ice-cold PBS and were then collected in kinase lysis buffer (10 mM Hepes (pH 8.0), 50 mM beta -glycerophosphate, 70 mM NaCl, 1% Triton) plus 1 mM sodium vanadate, and protease inhibitors were added before use. After centrifugation at 15,000 × g for 10 min, 15-35 µg of the lysates were assayed in duplicate for kinase activities. GST-PTG and MAP kinase assays were performed at 37 °C for 10 min in the presence of 50 mM Hepes (pH 7.4), 10 mM MgCl2, and 40 µM [gamma -32P]ATP (3000 cpm/pmol), using as substrate 10 µg of GST-PTG or 2.5 µg of MAP2 protein, respectively. Protein kinase A assays were performed at 37 °C for 2 min as above, using 5 µg of GST-G40 as substrate, in the absence and presence of 1 mM dibutyryl cAMP. Reactions were terminated by the addition of SDS-sample buffer. Samples were analyzed by SDS-PAGE and autoradiography, substrate proteins were excised from the dried gels, and 32P incorporation was measured by liquid scintillation counting.

Assay of PP1 Activity

3T3-L1 adipocytes were washed three times with ice-cold PBS and were then harvested in PP1 homogenization buffer (50 mM Hepes (pH 7.2), 2 mM EDTA, 0.2% beta -mercaptoethanol, and 2 mg/ml glycogen) plus protease inhibitors. Cells were lysed by sonication, and nuclei and cell debris were pelleted by centrifugation at 2,500 × g for 5 min. Where indicated, the resulting post-nuclear supernatant (PNS) was subjected to sequential centrifugation to prepare plasma membranes (10,000 × g, 15 min) and to separate glycogen-enriched pellets from the cytosol (100,000 × g, 1 h). Particulate fractions were resuspended in homogenization buffer using a 23-gauge needle. For PP1 assays, 1-3 µg of cellular fraction was preincubated in PP1 homogenization buffer (20-µl final volume) containing 4.5 nM okadaic acid for 2 min at 37 °C. Reactions were initiated by the addition of 10 µl (15 µg, 5 µM final) of 32P-labeled phosphorylase a (3 nM okadaic acid, 5 mM caffeine final). After 5-10 min, the reactions were terminated by the addition of 90 µl of ice-cold 20% trichloroacetic acid and 5 µl of 2% BSA (modified from Ref. 19). Samples were incubated for 10 min on ice, and precipitated protein was pelleted by a 2-min 15,000 × g centrifugation spin. Phosphate released into the supernatant was measured by liquid scintillation counting. For Lineweaver-Burk analysis, PP1 activity was measured using 0.5 µg of PNS fraction as above and 1, 2, 3, 4, and 6 µM final concentrations of phosphorylase substrate. In the absence of GST-PTG, samples were incubated at 37 °C for 2.5, 5, 7.5, and 10 min; in the presence of GST-PTG, samples were incubated for 1, 2, 4, and 5 min to ensure that maximal dephosphorylation did not exceed 25% of the substrate added. Reactions were terminated and quantitated as above, and results were analyzed using Cricket Graph (Cricket software). [32P]Phosphorylase a (~2000 cpm/pmol) was prepared as described previously (14).

Determination of PTG Binding Affinities

For phosphorylase a binding measurements, 5 µg of immobilized GST-PTG was resuspended in PP1 homogenization buffer plus 200 mM NaCl and 0.2% BSA. 32P-Labeled phosphorylase a was added to final concentrations of 1, 5, 10, and 15 µM (final volume 30 µl). Samples were incubated at 4 °C with gentle mixing for 30 min and were then washed three times with buffer. Phosphorylase a binding was determined by liquid scintillation counting. Parallel incubations using immobilized GST-PTP1B protein were subtracted as blanks for each phosphorylase concentration. For PP1 binding measurements, immobilized GST-PTG was incubated with increasing amounts of bacterial lysate in PP1 homogenization buffer containing recombinant PP1alpha . Samples were treated as above, except that binding was analyzed by anti-PP1 immunoblotting and ECL detection. Standard curves of PP1 protein were included on the immunoblots. Autoradiograms were analyzed by computer-assisted video densitometry using a Bio Image system (Millipore).

Other Procedures

Eluted DARPP-32 was thiophosphorylated as described (20). Following thiophosphorylation, polyhistidine-tagged DARPP-32 was rebound to Ni-NTA agarose beads, washed extensively, and was then eluted and concentrated as above.


RESULTS

PTG Expression Is Increased upon 3T3-L1 Differentiation

We have recently identified by two-hybrid screening a novel glycogen-targeting subunit of PP1 from 3T3-L1 adipocytes, termed PTG (1). This protein appears to act as a molecular scaffold for glycogen metabolism and can dramatically increase glycogen synthesis upon overexpression in tissue culture cells. To determine whether PTG expression is correlated with the increase in metabolic activity and insulin responsiveness observed following 3T3-L1 differentiation, PTG expression was examined in fibroblasts and fully differentiated adipocytes by Northern analysis. A single hybridizing mRNA species of 3 kilobases was identified, which was dramatically up-regulated following adipogenesis (Fig. 1). These results correlate PTG expression with 3T3-L1 adipocyte differentiation, suggesting a critical role for PTG in the regulation of glycogen synthesis in 3T3-L1 adipocytes.


Fig. 1. PTG expression is increased upon 3T3-L1 differentiation. Total RNA from 3T3-L1 fibroblasts and fully differentiated adipocytes was prepared, and Northern blot analysis was performed as described under "Experimental Procedures." PTG and beta -actin mRNA bands are indicated.
[View Larger Version of this Image (74K GIF file)]

PP1 and Phosphorylase a Bind GST-PTG in Vitro

We have previously demonstrated (1) that PTG can form specific complexes with PP1, phosphorylase a, phosphorylase kinase, and glycogen synthase, the key enzymatic regulators of glycogen synthesis. To better characterize the protein-protein interactions of these enzymes with PTG, the binding affinities of GST-PTG fusion protein for PP1 and phosphorylase a were determined. Immobilized GST-PTG was incubated with varying amounts of recombinant PP1alpha , the beads were washed and subjected to SDS-PAGE, and binding was quantitated by densitometry scanning of anti-PP1alpha immunoblots. Binding was saturated at 850 nM PP1, with an EC50 of approximately 335 ± 18 nM (Fig. 2A). The affinity of PTG for glycogen phosphorylase was measured next. Varying amounts of 32P-labeled phosphorylase a were incubated with immobilized GST-PTG, the beads were washed extensively, and binding was determined by liquid scintillation counting. As seen in Fig. 2B, phosphorylase a bound to PTG with an EC50 of 5.45 ± 0.14 µM. In contrast to the results of Doherty et al. (21), these data confirm earlier results demonstrating that PTG can directly associate with phosphorylase a (1).


Fig. 2. Affinity of PTG for PP1 and phosphorylase a binding. A, PP1 binding to PTG. The affinity of bacterially expressed PP1alpha for immobilized GST-PTG was measured as described under "Experimental Procedures." Inset, duplicate lanes of a representative anti-PP1alpha immunoblot quantitated by densitometry scanning. Results are representative of three independent experiments. B, phosphorylase binding to PTG. The affinity of 32P-labeled phosphorylase a for immobilized GST-PTG was measured as described under "Experimental Procedures." Results are representative of two experiments, each performed in duplicate.
[View Larger Version of this Image (16K GIF file)]

PTG Increases the Affinity of PP1 for Phosphorylase a

We examined the role of PTG in both the subcellular targeting and the regulation of PP1 specific activity. GST-PTG addition to a 3T3-L1 adipocyte PNS fraction, followed by differential centrifugation, resulted in a dose-dependent, 4-6-fold increase in PP1 activity in the glycogen-enriched fraction (Fig. 3A, GP). PTG addition to 3T3-L1 lysates also reduced the amount of PP1 activity targeted to the plasma membrane fraction (Fig. 3A, PM), indicating that changes in the level of PTG expression can impact on the cellular distribution of PP1 activity (1).


Fig. 3. PTG increase PP1 specific activity against phosphorylase a. A, IPTG targets PP1 to glycogen in 3T3-L1 lysates. The indicated amounts of soluble GST-PTG was added to 700 µl (~500 µg) of a PNS fraction from 3T3-L1 adipocytes, and samples were gently mixed for 1 h at 4 °C. Plasma membrane and glycogen-enriched fractions were then prepared, and PP1 activity against 32P-labeled phosphorylase a was measured in both fractions as described under "Experimental Procedures." Results are representative of four experiments, each performed in triplicate. B, PTG increases PP1 specific activity in 3T3-L1 PNS fraction. The indicated concentrations of soluble GST-PTG were added to a 3T3-L1 PNS fraction. Samples were mixed for 30-60 min at 4 °C, and PP1 assays were then performed. Results are representative of five experiments. C, Lineweaver-Burk analysis of PP1 activity. GST-PTG (100 nM) was added to 3T3-L1 adipocyte PNS fractions as in B, and Lineweaver-Burk enzymatic analysis was performed as described under "Experimental Procedures." Results are representative of four experiments, each performed in duplicate. D, specificity of PP1 activation by PTG. 100 nM soluble GST-PTG was added to a 3T3-L1 PNS fraction as in B. PP1 assays were performed in triplicate using either phosphorylase a (Phos a) or HSL as substrate. Control specific activities were approximately 1 and 0.5 pmol of PO4 released/min for phosphorylase a and HSL, respectively.
[View Larger Version of this Image (31K GIF file)]

Since PTG forms stable complexes with PP1 substrate proteins, it is possible that PTG can also modulate PP1 specific activity independently of glycogen localization. To test this possibility, varying amounts of soluble GST-PTG were added to 3T3-L1 adipocyte PNS fractions, and then PP1 activity was measured. PTG caused a dose-dependent 2-fold increase in PP1 specific activity against phosphorylase a (Fig. 3B), whereas addition of 500 nM GST protein had no effect on PP1 activity (data not shown). Lineweaver-Burk analysis revealed that PTG decreased the Km of PP1 for phosphorylase a 5-fold, while having no effect on the Vmax (Fig. 3B). Similar results were obtained in a glycogen-free, cytosolic fraction (data not shown), indicating that the stimulation of PP1 activity was independent of glycogen targeting. GST-PTG also caused a dose-dependent 3-fold increase in bacterially expressed PP1alpha activity against phosphorylase a (data not shown). GST-PTG was completely soluble and did not pellet upon ultracentrifugation in the absence of glycogen, possibly explaining differences with the results of Doherty et al. (21).

The effects of PTG on PP1 activity were dependent on the substrate used in the phosphatase assay. HSL is a lipid-metabolizing enzyme, which is dephosphorylated by PP1 in response to insulin stimulation of adipocytes. Although GST-PTG addition to a 3T3-L1 adipocyte PNS fraction increased PP1 specific activity 2-fold against phosphorylase a (Fig. 3D, Phos a), in parallel assays, there was no change in PP1 activity when 32P-labeled hormone-sensitive lipase was used as substrate (Fig. 3D, HSL). Thus PTG regulates PP1 specific activity by both targeting the phosphatase to glycogen and also by selectively binding and co-localizing certain substrates with PP1.

PTG Is Not a Target of Intracellular Signaling

Because PTG is likely to play a critical role in the regulation of glycogen synthesis by insulin, we examined whether PTG might be phosphorylated in response to hormone treatment. Although the putative phosphorylation sites previously suggested for RGL (10, 22) are not conserved in PTG (1), the possible phosphorylation of other residues on PTG was examined. CHO-IR cells transiently transfected with FLAG-PTG were labeled with [32P]orthophosphate and exposed to either 100 nM insulin or 10 µg/ml forskolin for 5 min. PTG was immunoprecipitated with anti-FLAG antibodies and subjected to SDS-PAGE followed by autoradiography. PTG exhibited a low basal state of phosphorylation, which was not changed by either treatment (Fig. 4A). In replicate cultures, insulin or forskolin exposure increased MAP kinase or protein kinase A activity 3- and 5-fold, respectively (Fig. 4B and data not shown).


Fig. 4. PTG is not phosphorylated in vivo or in vitro. A, PTG phosphorylation in CHO-IR cells. CHO-IR cells, transiently transfected with a FLAG-PTG construct, were labeled with [32P]orthophosphate. Following a 5-min treatment with either 100 nM insulin or 10 µg/ml forskolin, cells were lysed, and anti-FLAG immunoprecipitations were performed and analyzed by SDS-PAGE and autoradiography at -80 °C for 2 days. FLAG-PTG is indicated by arrow. B, MAP kinase activation in CHO-IR cells. Replicate plates of cells from A were stimulated and lysed in kinase buffer. MAP kinase activity was measured in vitro using purified MAP2 protein and [gamma -32P]ATP. Samples were separated by SDS-PAGE and were analyzed by autoradiography and scintillation counting. C, PTG is not phosphorylated by kinases in 3T3-L1 adipocyte lysates. Fully differentiated 3T3-L1 adipocytes were stimulated for 5 min with either 100 nM insulin, 10 µg/ml forskolin, 100 ng/ml EGF, or 100 nM TPA. Cell lysates were prepared, and in vitro PTG kinase assays were performed using [gamma -32P]ATP and GST-PTG as described under "Experimental Procedures." Samples were analyzed by SDS-PAGE and autoradiography. Coomassie-stained GST-PTG is indicated by the arrow. GST-PTG protein was omitted from the assay in lane 1. Treatment lanes: 1 and 2, basal; 3, insulin; 4, forskolin; 5, EGF; 6, TPA. In parallel assays, MAP kinase activity was stimulated 3-, 2-, and 1.2-fold by insulin, EGF, or TPA, respectively, whereas forskolin increased protein kinase A activity 4-fold (data not shown). Results are representative of two experiments, each performed in duplicate.
[View Larger Version of this Image (48K GIF file)]

To determine whether 3T3-L1 adipocytes contained a protein kinase capable of phosphorylating PTG, in vitro phosphorylation assays were performed using PTG as substrate. Cells were exposed to a variety of agents, and cellular lysates were prepared and incubated with GST-PTG and [gamma -32P]ATP. Samples were then analyzed by SDS-PAGE and autoradiography. As seen in Fig. 4C, GST-PTG was not phosphorylated in vitro by basal extracts (lane 1 versus 2). Further stimulation of 3T3-L1 adipocytes with either insulin or forskolin did not lead to the activation of a PTG kinase (Fig. 4C, lanes 3 and 4). EGF or TPA treatment of cells also did not result in any measurable phosphorylation of GST-PTG in vitro (Fig. 4C, lanes 5 and 6). Finally, PTG was also not phosphorylated in vitro by purified MAP kinase or protein kinase A catalytic subunit (data not shown), further indicating that PTG is not a physiological substrate for insulin- or cAMP-activated kinases.

Insulin Does Not Change the Subcellular Distribution of PP1

Translocation of PP1 to and from the glycogen particle in response to the phosphorylation of RGL has been suggested to underlie hormonal regulation of PP1 activity (10, 22). Although PTG is not phosphorylated in response to external stimuli, possible changes in the cellular distribution of PP1 following insulin treatment were examined. Primary rat adipocytes were isolated and exposed to 10 nM insulin for 30 min, and cellular fractions were prepared by differential centrifugation. Insulin induced a translocation of GluT-4 protein from the low density microsomal fraction to the plasma membrane fraction (Fig. 5A). However, insulin stimulation did not modulate PP1alpha protein levels in any fraction, including the low density microsomal fraction, which contains the glycogen pellet (Fig. 5B); identical results were obtained using an anti-PP1gamma antibody (data not shown). Further insulin or forskolin treatment of 3T3-L1 adipocytes also did not cause a detectable translocation of PP1 between cellular fractions (data not shown). Taken together, these data indicate that the regulation of PP1 activity by insulin, or agents that elevate intracellular cAMP levels, occurs independently of PP1 translocation.


Fig. 5. Effects of insulin on the subcellular distribution of GluT-4 and PP1. Primary rat adipocytes were incubated for 30 min in the absence and presence of 10 nM insulin. Cells were homogenized, and subcellular fractions were prepared by differential centrifugation as described under "Experimental Procedures." Proteins were separated by SDS-PAGE, transferred to nitrocellulose, and probed with an anti-GluT-4 (A) or an anti-PP1alpha (B) antibody. Cyto, cytosol; LDM, low density microsomes; PM, plasma membrane; HDM, high density microsomes; M/N, mitochondria and nuclei. Odd lanes are from basal adipocytes, and even lanes are from insulin-stimulated cells. The glycogen-enriched pellet is present in the low density microsomes under these fractionation conditions.
[View Larger Version of this Image (20K GIF file)]

PTG Decreases the Inhibition of PP1 by DARPP-32

PP1 is maintained in a low activity state in 3T3-L1 adipocytes by the binding of phosphorylated DARPP-32.3 Previous studies (23) suggested that insulin may activate PP1 in primary rat adipocytes by inducing the dephosphorylation and disassociation of this peptide. The role of PTG in modulating the regulation of PP1 activity by DARPP-32 was investigated. Thiophosphorylated DARPP-32 specifically inhibited PP1 activity in 3T3-L1 lysates (Fig. 6), with a Ki of 3 nM, consistent with previous results (20). Addition of purified GST-PTG to the lysates caused a rightward shift in the inhibition curve of DARPP-32 (Ki 30 nM, Fig. 6), indicating that PTG lowers the binding affinity of DARPP-32 for PP1. These data suggest that a decrease in the cellular phospho-DARPP-32 concentration in response to insulin might result in the preferential activation of PP1 bound to PTG.


Fig. 6. PTG decreases DARPP-32 inhibition of PP1 activity. PNS fractions from fully differentiated 3T3-L1 adipocytes were prepared. Following addition of GST-PTG as in the legend to Fig. 3, PP1 activity was measured in the presence of the indicated concentrations of thiophosphorylated DARPP-32. Assays were incubated at 37 °C for 8 min, and results are averaged from two experiments, each performed in triplicate.
[View Larger Version of this Image (20K GIF file)]


DISCUSSION

The regulation by insulin of enzymes involved in glycogen synthesis is primarily mediated by the activation of PP1 (2). The activities of glycogen synthase, phosphorylase a, and phosphorylase kinase are modulated by insulin via a mechanism involving their net dephosphorylation, resulting in an increase in glucose storage as glycogen. The paradoxical dephosphorylation of only a limited number of proteins by insulin, despite the ubiquitous presence of PP1 in nearly all cellular compartments, has yet to be explained. Mechanisms must exist for the establishment of discrete pools of PP1 which are preferentially activated by insulin.

PP1 is maintained in discrete subcellular compartments by association with specific targeting subunits. Three proteins have been identified which bind both glycogen and PP1, thus localizing PP1 at the glycogen particle. RGL was first purified from skeletal muscle (6, 7), and GL was subsequently purified from liver (8, 9). We have recently identified a third PP1 targeting subunit from 3T3-L1 adipocytes, termed PTG, for protein targeting to glycogen (1). PTG binds not only to PP1 and glycogen, but also to the primary enzymatic regulators of glycogen synthesis, namely glycogen synthase, phosphorylase kinase, and phosphorylase a (1). By co-localizing PP1 with its substrates at the glycogen particle, PTG acts as a scaffolding protein, assembling metabolic enzymes for the localized reception of intracellular signals.

Studies in different cell lines indicate that the level of PTG expression correlates with cellular metabolic activity. CHO-IR cells contain no endogenous PTG protein and exhibit a low basal rate of glycogen synthesis. Overexpression of PTG in these cells resulted in a 7-10-fold increase in glycogen synthesis (1). Differentiation of 3T3-L1 fibroblasts into lipid-containing adipocytes caused a dramatic increase in insulin-stimulated glycogen synthesis.3 PTG mRNA levels were strongly up-regulated during this differentiation protocol (Fig. 1), further indicating an important role for this protein in the regulation of glycogen synthesis by insulin.

PTG appeared to be capable of regulating PP1 specific activity in vitro by several mechanisms. Firstly, a GST-PTG fusion protein bound to PP1 with high affinity. Moreover, addition of GST-PTG to 3T3-L1 lysates resulted in a concentration-dependent translocation of PP1 to the glycogen-enriched pellet (Fig. 3A). The level of cellular expression of PTG would therefore presumably dictate the localization of PP1 at the glycogen particle (1). Secondly, GST-PTG also bound directly to phosphorylase a (Fig. 2B). Addition of GST-PTG to 3T3-L1 lysates, with no subsequent fractionation, caused a 2-fold increase in PP1 specific activity against phosphorylase a in vitro. Since PTG addition decreased the Km of PP1 for phosphorylase a 5-fold, without affecting the Vmax of the reaction, this increase in phosphatase activity resulted from the formation of a trimeric complex between PTG, PP1, and its substrate phosphorylase a. This effect of PTG on PP1 activity was restricted to specific proteins. Although HSL is a physiological substrate for PP1 in adipocytes and in vitro, PTG did not affect PP1 activity against this enzyme (Fig. 4D). Thus, PTG regulates PP1 activity against glycogen metabolic enzymes, both by targeting PP1 to glycogen and also by directly binding to and co-localizing specific PP1 substrate proteins.

The precise mechanism by which insulin activates glycogen-targeted PP1 activity remains unclear. Dent et al. (10) reported that the phosphorylation state of two protein kinase A consensus sites on the RGL glycogen targeting subunit regulated PP1 activity in vitro. However, this model has subsequently been disputed (11-15). PTG does not share the putative regulatory phosphorylation sites of RGL (1), and PTG was not phosphorylated in response to either insulin or forskolin treatment of CHO-IR cells (Fig. 4A). Additionally, neither agent could activate a kinase from 3T3-L1 adipocytes capable of phosphorylating exogenous PTG in vitro (Fig. 4C). Finally, insulin treatment had no effect on PP1 binding to PTG in CHO-IR cells (1), and insulin did not increase PP1 localization at the glycogen particle in either primary rat adipocytes (Fig. 5B) or 3T3-L1 adipocytes.3 Taken together, these results indicate that phosphorylation of PTG and/or changes in the affinity of PTG for PP1 do not mediate the hormonal regulation of PP1 activity targeted to glycogen.

In 3T3-L1 adipocytes, PP1 is maintained in a low basal activity state by DARPP-32 binding. DARPP-32 expression is dramatically induced upon differentiation of 3T3-L1 fibroblasts into adipocytes and correlates with a decrease in PP1 basal activity and increase in stimulation by insulin.3 Furthermore, DARPP-32 is expressed in pig brown fat (24), bovine adipose tissue (25), and in primary rat adipocytes, where it has been reported to be dephosphorylated in response to insulin (23). PP1 bound to PTG was resistant to inhibition by DARPP-32 (Fig. 6), in agreement with results with RGL (26). Since PTG reduces the affinity of DARPP-32 for PP1, glycogen-targeted PP1 activity may be more sensitive to possible insulin-induced dephosphorylation of inhibitor peptides in vivo. PTG may therefore not only increase PP1 specific activity against glycogen-targeted enzymes, but also may partially underlie the specific activation of glycogen-targeted PP1 by insulin. Additional work is needed to fully test this proposed model.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence and reprint requests should be addressed: Dept. of Cell Biology, Parke-Davis Pharmaceutical Research Division, 2800 Plymouth Rd., Ann Arbor, MI 48105. Tel.: 313-996-3960; Fax: 313-996-5668.
1   The abbreviations used are: PP1, type 1 protein phosphatase; RGL, muscle glycogen-binding regulatory subunit of PP1; GL, hepatic glycogen-targeting subunit of PP1; PTG, protein targeting to glycogen; DARPP-32, dopamine- and cAMP-regulated phosphoprotein, Mr = 32,000; HSL, hormone-sensitive lipase; GST, glutathione S-transferase; IPTG, isopropyl-1-thio-beta -D-galactopyranoside; BSA, bovine serum albumin; TPA, 12-O-tetradecanoylphorbol-13-acetate; PNS, post-nuclear supernatant; Ni-NTA, nickel-nitrilotriacetic acid; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; MAP, mitogen-activated protein; EGF, epidermal growth factor; MOPS, 4-morpholinepropanesulfonic acid.
2   J. A. Printen and A. R. Saltiel, manuscript in preparation.
3   M. J. Brady, A. C. Nairn, and A. R. Saltiel, submitted for publication.

REFERENCES

  1. Printen, J. A., Brady, M. J., and Saltiel, A. R. (1997) Science 275, 1475-1478 [Abstract/Free Full Text]
  2. Saltiel, A. R. (1996) Am. J. Physiol. 270, E375-E385 [Abstract/Free Full Text]
  3. Saltiel, A. R. (1994) FASEB J. 8, 1034-1040 [Abstract/Free Full Text]
  4. Hubbard, M. J., and Cohen, P. (1993) Trends Biochem. Sci. 18, 172-177 [CrossRef][Medline] [Order article via Infotrieve]
  5. Faux, M. C., and Scott, J. D. (1996) Trends Biochem. Sci. 21, 312-315 [CrossRef][Medline] [Order article via Infotrieve]
  6. Hubbard, M. J., and Cohen, P. (1989a) Eur. J. Biochem. 180, 457-465 [Abstract]
  7. Tang, P. M., Bondor, J. A., Swiderek, K. M., and DePaoli-Roach, A. A. (1991) J. Biol. Chem. 266, 15782-15789 [Abstract/Free Full Text]
  8. Moorhead, G., MacKintosh, C., Morrice, N., and Cohen, P. (1995) FEBS Lett. 362, 101-105 [CrossRef][Medline] [Order article via Infotrieve]
  9. Doherty, M. J., Moorhead, G., Morrice, N., Cohen, P., and Cohen, P. T. W. (1995) FEBS Lett. 375, 294-298 [CrossRef][Medline] [Order article via Infotrieve]
  10. Dent, P., Lavoinne, A., Nakielny, S., Caudwell, F. B., Watt, P., and Cohen, P. (1990) Nature 348, 302-308 [CrossRef][Medline] [Order article via Infotrieve]
  11. Robinson, L. J., Razzack, Z. F., Lawrence, J. C., Jr., and James, D. E. (1993) J. Biol. Chem. 268, 26422-26427 [Abstract/Free Full Text]
  12. Lin, T.-A., and Lawrence, J. C., Jr. (1994) J. Biol. Chem. 269, 21255-21261 [Abstract/Free Full Text]
  13. Wiese, R. J., Mastick, C. C., Lazar, D. F., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 3442-3446 [Abstract/Free Full Text]
  14. Lazar, D. F., Wiese, R. J., Brady, M. J., Mastick, C. C., Waters, S. B., Yamauchi, K., Pessin, J. E., Cuatrecasas, P., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 20801-20807 [Abstract/Free Full Text]
  15. Azpiazu, I., Saltiel, A. R., DePaoli-Roach, A. A., and Lawrence, J. C., Jr. (1996) J. Biol. Chem. 271, 5033-5039 [Abstract/Free Full Text]
  16. Waters, S. B., Yamauchi, K., and Pessin, J. E. (1995) Mol. Cell. Biol. 15, 2791-2799 [Abstract]
  17. Simpson, I. A., Yver, D. R., Hissin, P. J., Wardzala, L. J., Karnieli, E., Salans, L. B., and Cushman, S. W. (1983) Biochim. Biophys. Acta 763, 393-407 [Medline] [Order article via Infotrieve]
  18. Margolis, B., Bellot, F., Honegger, A. M., Ullrich, A., Schlessinger, J., and Zilberstein, A. (1990) Mol. Cell. Biol. 10, 435-441 [Medline] [Order article via Infotrieve]
  19. Cohen, P., Alemany, S., Hemmings, B. A., Resink, T. J., Strålfors, P., and Tung, H. Y. L. (1989) Methods Enzymol. 159, 390-408
  20. Nairn, A. C., Sihra, T. S., Ebens, A., Galagan, J., Greene, K., and Hettinger-Smith, B. (1995) Neuroprotocols 6, 108-111
  21. Doherty, M. J., Young, P. R., and Cohen, P. T. W. (1996) FEBS Lett. 399, 339-343 [CrossRef][Medline] [Order article via Infotrieve]
  22. Hubbard, M. J., and Cohen, P. (1989b) Eur. J. Biochem. 186, 701-709 [Abstract]
  23. Nemenoff, R. A., Blackshear, P. J., and Avruch, J. A. (1983) J. Biol. Chem. 258, 9437-9443 [Abstract/Free Full Text]
  24. Meister, B., Fried, G., Hökfelt, T., Hemmings, H. C., Jr., and Greengard, P. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8713-8716 [Abstract]
  25. Strålfors, P., Hemmings, H. C., Jr., and Greengard, P. (1989) Eur. J. Biochem. 180, 143-148 [Abstract]
  26. Strålfors, P., Hiraga, A., and Cohen, P. (1985) Eur. J. Biochem. 149, 295-303 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.